VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Slovin Discusses a Study Comparing Cardiovascular Events With Degarelix, Leuprolide in Prostate Cancer

Susan F. Slovin, MD, PhD
Published: Sunday, Feb 11, 2018


Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses a multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with prostate cancer and cardiovascular disease receiving degarelix, a GnRH receptor antagonist, or leuprolide, a GnRH receptor agonist.

Cardiovascular disease is the leading cause of death in men and women, Slovin says. Several years ago, it was found that there may be an increased risk of cardiovascular events in patients who receive a GnRH agonist, such as leuprolide, for the treatment of metastatic prostate cancer. Preliminary data has suggested that the amount of cardiovascular side effects in men treated with a GnRH antagonist, such as degarelix, might be fewer than in men who receive a GnRH agonist. 

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses a multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with prostate cancer and cardiovascular disease receiving degarelix, a GnRH receptor antagonist, or leuprolide, a GnRH receptor agonist.

Cardiovascular disease is the leading cause of death in men and women, Slovin says. Several years ago, it was found that there may be an increased risk of cardiovascular events in patients who receive a GnRH agonist, such as leuprolide, for the treatment of metastatic prostate cancer. Preliminary data has suggested that the amount of cardiovascular side effects in men treated with a GnRH antagonist, such as degarelix, might be fewer than in men who receive a GnRH agonist. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections: New York GU™: 10th Annual Interdisciplinary Prostate Cancer Congress® and other Genitourinary MalignanciesMay 30, 20181.5
Community Practice Connections™: Advancing RCC: A Focused Assessment of Recent Paradigm Shifts and Next Steps to Move the Field ForwardMay 30, 20181.5
Publication Bottom Border
Border Publication
x